REG - Novacyt S.A. - Notice of rescheduled AGM

Novacyt SAAnnouncement

21/06/2022 14:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220621:nRSU6683Pa&default-theme=true

RNS Number : 6683P  Novacyt S.A.  21 June 2022

 

 

Novacyt S.A.

 

("Novacyt", the "Company" or the "Group")

 

Notice of rescheduled AGM

 

Paris, France and Camberley, UK - 21 June 2022 - Novacyt (EURONEXT GROWTH:
ALNOV; AIM: NCYT), an international specialist in clinical diagnostics,
announces that the Company's Annual General Meeting (AGM), due to take place
earlier today, will be rescheduled and held on Wednesday 20 July at 10am
BST/11am CEST.

 

To function as a procedural meeting, the AGM requires a sufficient number of
shareholders to constitute a quorum to ensure the AGM is validly held in
accordance with French corporate law. This threshold has not been met and, in
accordance with Article 19 of Novacyt articles of association, the AGM has
been rescheduled.

 

The rescheduled AGM will be an open meeting exclusively held via video
conference and as usual, and in accordance with French corporate law, the AGM
comprises both ordinary and extraordinary general meetings.

 

Shareholders can register for the AGM and access the online meeting platform
by visiting

https://novacyt.eventcaster.co.uk (https://novacyt.eventcaster.co.uk) .

 

Voting will re-open from Friday 24 June 2022. Forms of Proxy already completed
and submitted and votes cast by electronic means for the first AGM remain
valid for all meetings subsequently convened with the same agenda (art. R.
225-77 of the French commercial code).

 

As this AGM is an open meeting there will be a facility to vote on-line during
the meeting for those shareholders who have not already voted. However, we
would encourage all shareholders to submit their votes well in advance of the
meeting date, by choosing one of the following options:

 

1.  Shareholders can download a copy of the Proxy voting form from
www.novacyt.com/investors (http://www.novacyt.com/investors) for completion
and return to investor.relations@novacyt.com until 10.59pm BST/11.59pm CEST on
Sunday 17 July 2022. All submissions must include an electronic signature and
be accompanied by evidence of shareholding, for example a share certificate or
statement of holding.

 

2.  Shareholders can vote on-line until 2pm BST/3pm CEST on Tuesday 19 July
2022 using the Votaccess portal http://www.actionnaire.cic-marketsolutions.eu
(http://www.actionnaire.cic-marketsolutions.eu) if securities held on Euronext
Growth are registered with any of the following banks: CIC, Natixis, Société
Générale, Caceis, Crédit Agricole, BP2S, BNP Retail, Bourse Direct, ODDO,
Rothschild Martin Maurel, Procapital, Citibank, Deutsche Bank or JP Morgan.

 

The Second Convening Notice of AGM will be published in the Bulletin des
Annonces Légales Obligatoires (BALO) and posted to nominative shareholders on
Friday 24 June 2022.

 

- End -

 

Contacts

Novacyt SA

David Allmond, Chief Executive Officer

James McCarthy, Chief Financial Officer

+44 (0)1276 600081

 

SP Angel Corporate Finance LLP (Nominated Adviser and Broker)

Matthew Johnson / Charlie Bouverat (Corporate Finance)

Vadim Alexandre / Rob Rees (Corporate Broking)

+44 (0)20 3470 0470

 

Numis Securities Limited (Joint Broker)

Freddie Barnfield / James Black / Duncan Monteith

+44 (0)20 7260 1000

 

Allegra Finance (French Listing Sponsor)

Rémi Durgetto / Yannick Petit

+33 (1) 42 22 10 10

r.durgetto@allegrafinance.com (mailto:r.durgetto@allegrafinance.com) ;
y.petit@allegrafinance.com (mailto:y.petit@allegrafinance.com)

 

FTI Consulting (International)

Victoria Foster Mitchell / Alex Shaw

+44 (0)20 3727 1000

victoria.fostermitchell@fticonsulting.com
(mailto:victoria.fostermitchell@fticonsulting.com) /
Alex.Shaw@fticonsulting.com (mailto:Alex.Shaw@fticonsulting.com)

 

FTI Consulting (France)

Arnaud de Cheffontaines

+33 (0)147 03 69 48

arnaud.decheffontaines@fticonsulting.com
(mailto:arnaud.decheffontaines@fticonsulting.com)

 

About Novacyt Group

The Novacyt Group is an international diagnostics business generating an
increasing portfolio of in vitro and molecular diagnostic tests. Its core
strengths lie in diagnostics product development, commercialisation, contract
design and manufacturing. The Company supplies an extensive range of
high-quality assays and reagents worldwide. The Group directly serves
microbiology, haematology and serology markets as do its global partners,
which include major corporates.

 

For more information, please refer to the website: www.novacyt.com
(http://www.novacyt.com)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOAZZGZVZMLGZZM